Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets

Lung cancer is the leading cause of cancer-related deaths in the world. Immune checkpoint inhibitors (ICI) stimulate cytotoxic lymphocyte activity against tumour cells. These agents are available for the treatment of non-small cell lung cancer (NSCLC) after failure of platinum-based therapy. One rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Aguiar, Pedro Nazareth, De Mello, Ramon Andrade, Barreto, Carmelia Maria Noia, Perry, Luke Alastair, Penny-Dimri, Jahan, Tadokoro, Hakaru, Lopes, Gilberto de Lima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703392/
https://www.ncbi.nlm.nih.gov/pubmed/29209522
http://dx.doi.org/10.1136/esmoopen-2017-000200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703392/
https://www.ncbi.nlm.nih.gov/pubmed/29209522
http://dx.doi.org/10.1136/esmoopen-2017-000200

Ejemplares similares